Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XL147 · 6 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | All subjects will receive single-agent XL147 dosed daily |
| Arm 1 | EXPERIMENTAL | XL147 (SAR245408) + letrozole |
| Arm 2 | EXPERIMENTAL | XL765 + letrozole |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | Continuous daily dosing |
| 3 | EXPERIMENTAL | Continuous daily dosing |
| Name | Type | Description |
|---|---|---|
| XL147 (SAR245408) | DRUG | dosed as capsules taken orally daily |
| XL765 (SAR245409) | DRUG | given orally twice daily as capsules |
| letrozole (Femara) | DRUG | given orally once daily as tablets |
| trastuzumab | BIOLOGICAL | administered by IV once every 3 weeks |
| paclitaxel | DRUG | administered by IV once every week |
| XL147 (SAR245408), | DRUG | Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing |
| carboplatin | DRUG | Intravenous injection dosed once every three weeks |
| Erlotinib | DRUG | Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing |
Inclusion Criteria: * The subject has a histologically confirmed diagnosis of EC (endometrioid, serous, clear cell adenocarcinoma, adenosquamous carcinoma, or mixed histology, any grade) that is advanced (ie, persistent, locally advanced) or recurrent, and is incurable by standard therapies and has...
Top 20 of 47 competitors
XL147 is an investigational small molecule being studied for the treatment of cancer, including endometrial cancer, breast cancer, and non-small cell lung cancer. It was evaluated in clinical trials for solid tumors and lymphoma. XL147 is not approved and remains in clinical development.
XL147 is a small molecule that targets the PI3K pathway. It was studied as a single agent and in combination with other therapies for the treatment of various cancers, including endometrial cancer and non-small cell lung cancer.
XL147 is being developed by Sanofi, a company traded on the stock exchange under the ticker SNY. Sanofi conducted clinical trials to evaluate the safety and efficacy of XL147 in patients with cancer.
XL147 has completed Phase 1 and Phase 2 clinical trials. The Phase 2 trial studied XL147 in advanced or recurrent endometrial carcinoma. However, XL147 is still investigational and has not been approved by regulatory authorities.
XL147 has been studied in several clinical trials, including NCT00486135, a Phase 1 study in adults with solid tumors or lymphoma; NCT00692640, a Phase 1 study combining XL147 with erlotinib; NCT00756847, a Phase 1 study combining XL147 with paclitaxel and carboplatin; and NCT01013324, a Phase 2 study in endometrial carcinoma.
Yes, XL147 is also known as SAR245408. Clinical trials for XL147 often list the drug under the name SAR245408, as seen in studies such as NCT00486135 and NCT00692640.